Not willing to avoid grapefruit, grapefruit juices, grapefruit hybrids, Seville oranges, pummelos, and exotic citrus fruits from 7 days prior to the dose of study medication and during the entire study; orange juice is allowed
Patients must be willing and able to avoid consuming food and beverages containing grapefruit, star fruit or Seville oranges while on ibrutinib study therapy
Consumed grapefruit, grapefruit products, Seville oranges, or star fruit within 3 days prior to starting venetoclax
Participants receiving any medications or substances that are moderate and strong inhibitors or inducers of cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4), including enzyme-inducing anti-epileptic drugs (EIAEDs) within 14 days before the first dose of ponatinib will be excluded; this category includes phenobarbital, phenytoin, fosphenytoin, primidone, carbamazepine, and oxcarbazepine\r\n* NOTE: participants must avoid consumption of Seville orange (and juice), grapefruit or grapefruit juice, grapefruit hybrids, pummelos and exotic citrus fruits from 7 days prior to the first dose of study drug and during the entire study treatment period
In addition, grapefruit, grapefruit juice, seville oranges and star fruit should be avoided, as they inhibits CYP3A4
Participant consumed grapefruit or grapefruit products within 3 days prior to the first dose of study drug.
Consumption of grapefruits, grapefruit products, Seville oranges (including marmalade that contains Seville oranges), or star fruit within 3 days prior to the first dose of venetoclax.
Is unwilling to exclude grapefruit juice, Seville oranges and grapefruit from the diet and all foods that contain those fruits from time of enrollment to while on study.
For subjects in expansion cohort only: Ingestion of any food or drink containing grapefruit or Seville oranges, or St. John´s wort, within 7 days prior to receiving the first dose of AMG 330
Willingness to avoid the ingestion of grapefruit and Seville oranges (as well as other products containing these fruits, e.g. grapefruit juice or marmalade) during the study
Received the following agents within 7 days prior to the first dose of venetoclax:\r\n* Steroid therapy for anti-neoplastic intent \r\n* Strong and moderate CYP3A inhibitors \r\n* Strong and moderate CYP3A inducers\r\n* Consumed grapefruit, grapefruit products, Seville oranges (including marmalade containing Seville oranges), or star fruit within 3 days prior to the first dose of venetoclax
Subject has consumed grapefruit, grapefruit products, seville oranges (including marmalade containing seville oranges) or star fruit within 3 days prior to the initiation of study treatment
Participant has consumed grapefruit, grapefruit products, Seville oranges (including marmalade containing Seville oranges) or Starfruit within 3 days prior to the initiation of study treatment.
Patients must avoid consumption of grapefruit, pomegranates, starfruit, Seville oranges or products containing the juice of each during the entire study and preferably 7 days before the first dose of study medications; orange juice is allowed
Patients requiring the following agents within 7 days prior to the first dose of venetoclax are excluded:\r\n* Steroid therapy for anti-neoplastic intent\r\n* Strong CYP3A inhibitors\r\n* Strong CYP3A inducers\r\n* Consumed grapefruit, grapefruit products, Seville oranges (including marmalade containing Seville oranges), or star fruit within 3 days prior to the first dose of venetoclax\r\n* NOTE: moderate CYP3A inhibitors and inducers should be used with caution and an alternative medication used, whenever possible
Consuming grapefruit, grapefruit products, Seville oranges, or star fruit within 7 days of starting venetoclax
Willingness to avoid the ingestion of grapefruit and Seville oranges (as well as other products containing these fruits, e.g. grapefruit juice or marmalade) during the study, as these may affect selumetinib metabolism
Consumption of grapefruit, grapefruit hybrids, pummelos, star-fruit, Seville oranges or products containing the juice of each within 7 days prior to study registration.
Participant has consumed grapefruit, grapefruit products, Seville oranges (including marmalade containing Seville oranges) or Star fruit within 3 days prior to the initiation of study treatment.
Consumption of grapefruit and related fruits within 7 days prior to initiation of study drug
Use of strong or moderate inhibitors and inducers of cytochrome P450 (CYP) 3A4, including certain herbal medications (eg, St. John's Wort) and consumption of grapefruit or grapefruit juice within 14 days or 5 x the half?life (whichever is longer) prior to the first dose of study drug.
Received the following agents within 7 days prior to the first dose of venetoclax:\r\n* Strong and moderate CYP3A inhibitors\r\n* Strong and moderate CYP3A inducers\r\n* Consumed grapefruit, grapefruit products, Seville oranges (including marmalade containing Seville oranges), or star fruit within 3 days prior to the first dose of venetoclax
Patients must avoid grapefruit, grapefruit juice, supplements containing grapefruit juice, star fruit, and Seville oranges during the entire study, starting 7 days prior to the first dose of study drug
Consumption of Seville oranges, grapefruit, grapefruit hybrids, grapefruit juice, pommelos, or exotic citrus fruits, from 1 day prior to the first dose of study treatment(s) until the last dose of study drug
Willingness to avoid the ingestion of grapefruit and Seville oranges (as well as other products containing these fruits, e.g. grapefruit juice or marmalade) during the study
Consumed grapefruit, grapefruit products, Seville oranges, or star fruit within 7 days of starting study drugs
Consumption of grapefruit, grapefruit juice, pomegranates, star fruits, Seville oranges or products within 7 days prior to first dose
Not willing to avoid grapefruit, grapefruit juices, grapefruit hybrids, Seville oranges, pummelos, and exotic citrus fruits from 7 days prior to the dose of study medication and during the entire study; NOTE: orange juice is allowed
Consumption of grapefruit, grapefruit juice, grapefruit hybrids, pomelos, pomegranates, star fruits, Seville oranges or related products within 7 days prior to first dose
Not willing to avoid grapefruit, grapefruit juices, grapefruit hybrids, Seville oranges, pummelos, and exotic citrus fruits from 14 days prior to the dose of study medication, throughout the study, and until 2 weeks after the last dose of AZD1775 due to potential cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4) interaction with the study medication; orange juice is allowed
Is unwilling to exclude grapefruit juice, Seville oranges and grapefruit from the diet and all foods that contain those fruits from time of enrollment to while on study
Grapefruit-containing food or beverages within 5 days before the first dose of study drug. Note that grapefruit-containing food and beverages are not permitted during the study.
Patients currently taking warfarin, tamoxifen, phenytoin, diclofenac, tolbutamide, or ibuprofen are excluded secondary to potential inhibition of cytochrome P450 2C9 (CYP2C9); in addition patients that consume grapefruit juice and Seville orange juice must not consume these during the study
Participants taking a drug known to be strong inhibitors or inducers of isoenzyme CYP3A; participant must be off CYP3A inhibitors and inducers for at least 7 days prior to planned start of study treatment; NOTE: participants must avoid consumption of Seville orange (and juice), grapefruit or grapefruit juice, grapefruit hybrids, pummelos and exotic citrus fruits from 7 days prior to planned start of study treatment and during the entire study treatment period due to potential CYP3A4 interaction
Is willing to abstain from grapefruit and Seville oranges (or juice) from 7 days before the first dose until study completion
Participants taking a drug known to be a strong inhibitor or inducer of isoenzyme CYP3A; participant must be off CYP3A inhibitors and inducers for at least 14 days prior to starting study drug; NOTE: participants must avoid consumption of Seville oranges (and juice), grapefruits or grapefruit juice, grapefruit hybrids, pomelos and exotic citrus fruits from 7 days prior to the first dose of study drug and during the entire study treatment period
Grapefruit and grapefruit juice (CYP3A4 inhibitor), Seville oranges and star fruit consumption is not permitted during the study
Patients must not be taking ketoconazole, dexamethasone, the dysrhythmic drugs (terfenadine, quinidine, procainamide, sotalol, probucol, bepridil, indapamide or flecainide), haloperidol, risperidone, rifampin, grapefruit, or grapefruit juice within two weeks of randomization and during the course of therapy; topical and inhaled steroids are permitted
Is unwilling to exclude grapefruit juice, Seville oranges and grapefruit from the diet and all foods that contain those fruits from time of enrollment to while on study
Is unwilling to exclude grapefruit juice, Seville oranges, and grapefruit from the diet and all foods that contain those fruits from time of enrollment to while on study
Is unwilling to exclude grapefruit juice, Seville oranges and grapefruit from the diet and all foods that contain those fruits from time of enrollment throughout their time on study
Participants unwilling to exclude grapefruit juice and grapefruit from their diet.
Known strong inducers or inhibitors of CYP3A4/5, including grapefruit, grapefruit hybrids, pomelos, star-fruit, and Seville oranges
Grapefruit, Seville oranges or products containing either juice
Grapefruit, grapefruit juice, and other foods known to inhibit cytochrome P450 and PgP activity may increase everolimus exposures and should be avoided during treatment.
Consumption of Seville oranges, grapefruit, grapefruit hybrids, grapefruit juice, pommelos, or exotic citrus fruits, from 1 day prior to the first dose of study treatment(s) until the last dose of study drug.
Received the following agents within 7 days prior to the first dose of venetoclax: steroid therapy for anti-neoplastic intent; strong and moderate cytochrome P450 (CYP) 3A4 inhibitors or inducers; grapefruit/grapefruit products, seville oranges or star fruit within 3 days prior to the first dose of venetoclax
Consumed grapefruit or grapefruit products, Seville oranges (including marmalade containing Seville oranges), or star fruit within 3 days prior to the first dose of study treatment
Participant has consumed grapefruit, grapefruit products, Seville oranges (including marmalade containing Seville oranges) or Starfruit within 3 days prior to the initiation of study treatment.
Patients must not eat grapefruit or drink grapefruit juice or plan to eat or drink them during study therapy
Consumed grapefruit or grapefruit products, seville oranges (including marmalade containing seville oranges), or star fruit within 3 days prior to the first dose of study treatment
Patients should avoid CYP3A4 inhibiting foods including grapefruit and Seville orange juice
Patients using Seville orange, star fruit, grapefruit and their juices, and St. John's Wort
Not willing to avoid grapefruit, grapefruit juices, grapefruit hybrids, Seville oranges, pomelos, and exotic citrus fruits from 7 days prior to the dose of study medication and during the entire study due to potential cytochrome P450 3A4 (CYP3A4) interaction with the study medication; orange juice is allowed
Consumption of Seville oranges, grapefruit, grapefruit hybrids, grapefruit juice, pommelos, or exotic citrus fruits, from 1 day prior to the first dose of study treatment(s) until the last dose of study drug.
Grapefruit juice (potent cytochrome P450 CYP3A4 enzyme inhibitor).
RECURRENT/ PROGRESSIVE DIPG (STRATUM 1): Patients must agree to avoid grapefruit or grapefruit juice and Seville (sour) oranges during the entire study
NON-PROGRESSED DIPG (STRATUM 2): Patients must agree to avoid grapefruit or grapefruit juice and Seville (sour) oranges during the entire study
Actual or potential cytochrome P450 (CYP) 3A interactions including: requirement for warfarin; use of strong and moderate CYP3A inhibitors or inducers within 7 days prior to first dose of venetoclax; or consumption of grapefruit, Seville oranges, or star fruit within 3 days prior to first dose of venetoclax
Intake of grapefruit, grapefruit juice, Seville oranges, or other products containing grapefruit or Seville oranges within 14 days prior to day 1
Intake of grapefruit, grapefruit juice, Seville oranges, or other products containing grapefruit or Seville oranges within 14 days prior to day 1 and during the study
Consumption of food or beverages containing grapefruit juice within 7 days of study drug dosing
Subject has consumed grapefruit or grapefruit products within 3 days prior to the first dose of study drug
Willingness to avoid the ingestion of grapefruit and Seville oranges (as well as other products containing these fruits, e.g. grapefruit juice or marmalade) during the study, as these may affect selumetinib metabolism
Willing to abstain from eating grapefruit or drinking grapefruit juice for the duration of the study
Patients who are currently receiving or consuming\r\n* Medications that are known strong inducers or inhibitors of cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4) =< 14 days of starting study treatment\r\n• Medications with a known risk of prolonging the QT interval or inducing Torsades de Pointes =< 7 days prior to start of study treatment\r\n* Amiodarone =< 180 days prior to start of study treatment\r\n* Grapefruit, grapefruit juice, pomegranates, star fruits, Seville oranges or products =< 7 days prior to start of study treatment\r\n* Warfarin (or derivatives)
Must abstain from grapefruit juice
Grapefruit-containing food or beverages within 5 days before the first dose of study drug. Note that grapefruit-containing food and beverages are not permitted during the study.
Seville oranges within 5 days before the first dose of study drugs and during the study.
Willingness to refrain from grapefruit juice for 7 days prior to and for 7 days during the study
Consumption of grapefruit or grapefruit juice is not permitted during the study; patients should not consume food or beverages containing the fruit or juice of grapefruits or Seville oranges within 7 days before the first dose of study drug and throughout the study
Consumed grapefruit juice or grapefruit containing products within 7 days of the first planned ranolazine dose
Participants who have taken any medicines that are inducers, inhibitors or substrates of select cytochrome (CYP) isozymes within the past 3 months will be excluded; participants who have consumed either grapefruit juice or Seville orange juice in the past 7 days will be excluded
Willingness to abstain from grapefruit juice, alcohol, and concomitant medications during study
Food or beverages containing grapefruit, Seville oranges, or Star fruit within 5 days before the first dose of study drugs. Note that food and beverages containing grapefruit, Seville orange, or Star fruit are not permitted during the study.
Food or beverages containing grapefruit within 5 days before the first dose of study drug. Note that food and beverages containing grapefruit are not permitted during the study.
Grapefruit-containing food or beverages within 5 days before the first dose of study drug. Note that grapefruit-containing food and beverages are prohibited during the study.
